drugset / Trial / NCT01200485
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
RandomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol. The safety of this treatment will also be studied.
Timeline
- Start
- 2011-04
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allopurinol | Small molecule | 300 mg | Intravenous |
| Subject | Rasburicase | Protein / enzyme biologic | 0.15 mg/kg | Intravenous |
| Subject | Rasburicase | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | Rasburicase | Protein / enzyme biologic | 3 mg | Intravenous |